<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-140613</identifier>
<setSpec>0034-9356</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Treatment of anemia in hip fracture surgery</dc:title>
<dc:description xml:lang="en">Repairing hip fractures is one of the most common surgical procedures and has greater morbidity and mortality. This procedure is also a process that involves a greater need for blood products. Numerous factors influence morbidity, mortality and the use of blood products: patient age, concomitant diseases and drug treatments that change hemostasis and hemorrhaging (preoperative, intraoperative and postoperative), which are usually significant. On top of all this is the presence in a high percentage of cases of preoperative anemia, which can have one or more causes. It is therefore essential to establish an appropriate management of perioperative anemia and optimize the transfusion policy. The aim of this review is to briefly analyze the epidemiology of hip fractures as well as establish a basis for treating perioperative anemia and transfusion policies, proposing guidelines and recommendations for clinical management based on the most current studies (AU)</dc:description>
<dc:creator>García Pascual, E</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Uno de los procesos quirúrgicos más frecuentes y con mayor morbimortalidad es la fractura de cadera. Adicionalmente, es uno de los procesos que comporta mayor consumo de sangre. En la morbimortalidad y consumo de sangre influyen numerosos factores: edad y patologías concomitantes de los pacientes, tratamientos medicamentosos que alteran la hemostasia y hemorragia, pre, intra o posquirúrgica, que suele ser importante. A todo ello se añade la presencia en un alto porcentaje de casos de una anemia preoperatoria que puede ser debida a una o más causas. Consecuentemente, es primordial plantear un adecuado manejo de la anemia perioperatoria y optimizar la política transfusional. El propósito de esta revisión es analizar brevemente la epidemiología de la fractura de cadera, así como establecer unas bases para el tratamiento de la anemia perioperatoria y política transfusional, proponiendo unas guías y recomendaciones de manejo clínico, con base en los trabajos más actuales (AU)</dc:description>
<dc:source>Rev Esp Anestesiol Reanim;62(supl.1): 57-62, jun. 2015. tab</dc:source>
<dc:identifier>ibc-140613</dc:identifier>
<dc:title xml:lang="es">Tratamiento de la anemia en cirugía de fractura de cadera</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d7668^s22073</dc:subject>
<dc:subject>^d28875</dc:subject>
<dc:subject>^d53702</dc:subject>
<dc:subject>^d29387^s22073</dc:subject>
<dc:subject>^d7668^s22000</dc:subject>
<dc:subject>^d6778^s22009</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d15204^s22073</dc:subject>
<dc:subject>^d755^s22057</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d19059</dc:subject>
<dc:subject>^d55027</dc:subject>
<dc:subject>^d5629^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>201506</dc:date>
</metadata>
</record>
</ibecs-document>
